Navigation Links
BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
Date:6/4/2008

MOUNTAIN VIEW, California, June 4 /PRNewswire-FirstCall/ -- BN ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its therapeutic vaccine candidate against prostate cancer.

A Phase I/II safety and tolerability study in 18 male patients with non-metastatic as well as hormone-insensitive prostate cancer has begun enrolment in the US. Secondary objectives of the trial include examining the ability of the vaccine to induce prostate antigen-specific immune responses, as well as clinical anti-tumor activity. Preliminary data is expected during second half year 2009.

The therapeutic vaccine, based on the company's MVA-BN(R) technology, is designed to generate cellular and humoral immune responses to PSA and PAP (prostate specific antigen and prostatic acid phosphatase), which are both well-known prostate cancer tumor targets.

Prostate cancer is, along with breast cancer, in the top three cancer market, each with more than 500,000 new diagnosed incidents globally per year and only limited treatment options.

Reiner Laus, MD, President & CEO of BN ImmunoTherapeutics said: "The initiation of clinical studies with our therapeutic prostate cancer vaccine advances our cancer portfolio and with both breast and prostate cancer vaccines in clinical development, we have now strengthened the cancer business area, which is an essential part of our group strategy going forward."

Located in Mountain View, California, BN ImmunoTherapeutics is a subsidiary of Bavarian Nordic, headquartered in Denmark.

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's business strategy is focused in three areas: biodefence, cancer and infectious diseases. Bavarian Nordic's proprietary and patented technology, MVA-BN(R), has been demonstrated in clinical trials to be one of the world's safest, multivalent vaccine vectors. Bavarian Nordic has ongoing contracts with the US government for the late-stage development and procurement of the company's third-generation smallpox vaccine, IMVAMUNE(R).

Bavarian Nordic is listed on the OMX Nordic Exchange Copenhagen under the symbol BAVA.

For more information, please visit: http://www.bavarian-nordic.com

"Safe Harbour" Statement under the Private Securities Litigation Reform Act of 1995:

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. No "forward-looking statement" can be guaranteed, and actual results may differ materially from those projected. Bavarian Nordic undertakes no obligation to publicly update any "forward-looking statement", whether as a result of new information, future events, or otherwise. Additional information regarding risks and uncertainties is set forth in the current Annual Report and in Bavarian Nordic's periodic reports, if any, which we incorporate by reference.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
2. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
6. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
7. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
8. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
9. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
10. Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms
11. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... CHRISTCHURCH, New Zealand , May 24, 2016 ... scanning and informatics solutions for the healthcare sector, has been ... the New Zealand Hi-Tech Awards 2016. Dr ... a fantastic acknowledgement for our team.  It,s really good to ... the burden healthcare internationally. Our products are used in 35 ...
(Date:5/24/2016)... VMS BioMarketing as senior vice president of sales, announced Andrea Heslin Smiley , ... the company,s business development and sales team, exploring new opportunities for VMS to empower ... ... ... ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 million people living ... survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather to ... , National Cancer Survivors Day® is an annual worldwide Celebration of Life that ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma ... drugs, biologics, consumer health and global clinical supply services, today announced two key ... the company’s continued investment and strategic growth plans in the Asia Pacific region. ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey ... , The 550 employees of Sun Health Senior Living (SHSL) may not ... reduces their doctor and prescription copays for the year, while holding the line on ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
(Date:5/26/2016)... BELLEVUE, Wash. (PRWEB) , ... May 26, 2016 ... ... a trusted provider of comprehensive treatment for eating disorders, is opening a brand ... facility will provide individuals ages 8-17 and their families with even more specialized ...
Breaking Medicine News(10 mins):